妇炎舒胶囊联合抗生素治疗慢性盆腔炎疗效分析

目的观察中药妇炎舒胶囊联合盐酸左氧氟沙星片和甲硝唑片治疗慢性盆腔炎患者的疗效和相关炎性因子的影响。方法收取118例湿热瘀结型慢性盆腔炎的患者,随机分为实验组(A组)和对照组(B组)各59例。A组给予妇炎舒胶囊56 d,B组妇炎舒胶囊模拟剂56 d,两组均服用盐酸左氧氟沙星片+甲硝唑片用药14 d。患者服药56 d后观察临床有效率及治疗前后血清中肿瘤坏死因子-α(Tumor necrosis factor,TNF-α),干扰素-γ(Interferon,IFN-γ)因子含量的变化;随访1个月经周期后观察者复发率及慢性盆腔痛情况。结果(1)A组中医证候积分有效率明显高于B组,且差异有统计学意义(P<0.01)。(2)治疗后A组患者外周血中TNF-α和IFN-γ的含量明显低于B组,具有显著统计学差异(P<0.01)。(3)A组随访复发率(10.17%vs 96.61%)和后遗盆腔痛(18.64%vs 86.44%)均显著低于B组(P<0.01)。结论中药妇炎舒胶囊联合抗生素治疗湿热瘀结型慢性盆腔炎疗效显著,并能够降低慢性盆腔炎的复发率和慢性盆腔痛,并能通过适当降低外周血中TNF-α、IFN-γ等炎性因子的形成,起到治疗作用。     

The PROFILE of assessment program for internal medicine internship of Sun Yat-Sen University

Objective: To reflectively look at the present methods by which the clinical competence of 5th-year medical students (i.e. interns) in Sun Yat-Sen University (SYSU) are assessed upon finishing internship rotation in internal medicine (IM).

Methods: Current procedures for the competence assessment of end-of-rotation IM interns in the First Affiliated Hospital of SYSU were reviewed, along with a point-by-point appraisal based on the PROFILE approach to structured assessment, and, whenever possible, suggestions for future improvement.

Results and discussions: On a scale of 1–10, with 10 being the best or the most ideal, our marks for current methods to assess end-of-rotation IM interns in terms of being Programmatic, Real-World, Outcome-based, Formative, Impactful, Learner-engaged, and Evaluation-guaranteed were 7, 9, 3, 4, 6, 8, and 1, respectively. The strengths, weaknesses as well as potential solutions in each of the seven aspects are also discussed separately.

Conclusions: Current assessment program for IM internship is strong in being programmatic, real-world, educationally impactful and learner engaged, and has room for further improvement in its time-based arrangements, relative shortage of feedback provision, as well as a systematic lack of quality control measures.     

沉默TRIM23基因抑制骨肉瘤细胞的增殖

目的 探讨TRIM23基因对骨肉瘤细胞增殖能力的影响.方法 应用Western blot实验检测TRIM23基因在骨肉瘤细胞中的表达;应用shRNA质粒转染骨肉瘤细胞系U2OS,通过MTT与平板克隆形成实验评估细胞增殖能力;应用Westernblot实验检测U2OS细胞Akt/P53/P21通路的表达改变.结果 TRIM23蛋白在骨肉瘤细胞中的表达高于成骨细胞;沉默TRIM23基因可以抑制骨肉瘤细胞的增殖能力;沉默TRIM23基因下调P-Akt表达,但总Akt的表达无明显改变,上调P53与P21的表达.结论 TRIM23在骨肉瘤细胞中表达升高,TRIM23能通过调节Akt/P53/P21通路影响骨肉瘤细胞的增殖.     

新型冠状病毒肺炎疫情后儿童维生素D营养状况调查

目的 调查新型冠状病毒肺炎疫情发生后儿童维生素D营养状况，并探讨实施严格疫情防控措施对儿童维生素D营养状况的影响。 方法 回顾性选取2020年2~8月常规体检合格儿童7 460例作为观察组，同时选取2019年2~8月（无疫情期）10 102例常规体检合格儿童作为对照组，比较两组血清25羟基维生素D［25-hydroxy vitamin D，25(OH)D］水平。同时将观察组与对照组中3~4月期间的体检儿童分别作为疫情防控亚组（n=1 710）和未防控亚组（n=2 877）。将研究对象分成5个年龄段（婴儿期、幼儿期、学龄前期、学龄期及青春期），比较疫情防控亚组和未防控亚组组间各年龄段儿童血清25(OH)D水平的差异。 结果 观察组3月和4月的血清25(OH)D水平均明显低于对照组（P<0.001）。疫情防控亚组各年龄段儿童血清25(OH)D水平均明显低于未防控亚组（P<0.001）。疫情防控亚组幼儿期、学龄前期、学龄期和青春期儿童维生素D充足率显著低于未防控亚组（P<0.001），较未防控亚组分别下降10.71%、18.76%、59.63%和56.29%。 结论 新型冠状病毒肺炎疫情严格防控措施可能导致儿童，尤其是学龄期和青春期儿童的维生素D水平明显降低，建议及时监测儿童维生素D水平并补充适量维生素D 制剂，在遵守防疫规定的前提下尽量增加户外日照时间。 引用格式:     

睾丸及附睾炎性病变体表牵涉痛与穴位敏化形成的联系

目的:观察睾丸及附睾炎性病变患者体表牵涉痛分布区与治疗该类疾病相关穴位的关系,通过动物实验进一步对比相关内脏器官体表敏化区与穴位的关系。方法:临床研究部分将93例睾丸、附睾炎患者临床体查确定的体表痛敏点进行总结分析,将其分布部位与临床治疗该类疾病常用穴位进行对比;动物实验部分观察雄性SD睾丸炎模型大鼠(n=8)、对照组(n=3)注射伊文思蓝(Evans Blue)后体表渗出点,与临床痛敏点和相关穴位对比。结果:临床观察93例睾丸、附睾炎患者体表痛敏点大多分布在下腹部及下肢内侧,腰部及会阴部也有部分分布,痛敏点分布范围与大部分治疗该类疾病常用穴位所处位置在同一区域,并有部分重叠;动物实验观察到体表Evans Blue渗出点与临床痛敏点分布情况高度相似。结论:睾丸、附睾炎性病变引发的体表痛敏点多数与治疗该类疾病的相关穴位所处位置重叠或邻近,提示这些疾病状态下的体表敏化点可能是穴位形成的主要原因。     

Systematic comparison of plasma EBV DNA,anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.